Comment & Analysis

Whether by luck or design Bristol-Myers Squibb had the advantage of a broad Opdivo label in lung ...

Heron Therapeutics could not have hoped for better timing for the release of positive pivotal data ...

The last year has seen a number of merger agreements between very similar medtech companies ...




Therapeutic Focus

Market Moving Events

EP Vantage Interviews